Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Despite the limitations of our study we

    2022-08-31


    Despite the limitations of our study we found a strong correlation between treatment location and time to completion of therapy. Moving forward, it is critical that these patients are recognized at the beginning of their care and efforts are made to ensure timely and coordinated care in order to improve compliance rates with RT. Using cancer navigators to help coordinate care between multiple sites and providers, providing patients with a treatment plan outline, and encouraging patients to meet with the 4μ8C oncologist who will perform their brachyther-apy at the start of therapy may help close the treatment duration gap. Several studies have noted improvement in care coordination with the use of cancer navigators including improved adherence to cancer ap-pointments [22]. Multi-institution studies are necessary to confirm this finding, and to further evaluate treatment duration on recurrence rates and disease specific survival.
    Authors' contribution
    Corinne Calo, DO: Primary author. Performed majority of the chart review and wrote the bulk of the abstract/manuscript.
    John Elliott, MPH, PhD: Helped to organize data and performed ma-jority of statistical analyses.
    Gary Reid, MD: Provided charts for chart review, helped in writing and editing the abstract and final paper.
    Aine Clements, MD: Provided charts for chart review, helped in writ-ing and editing the abstract and final paper. Performed statistical analy-sis and created figures for progression free survival and overall survival.
    Kellie Rath, MD: Primary investigator/mentor for project. Helped to design the project and data collection sheet. Helped in writing and editing the abstract and final paper.
    There are no conflicts of interest to disclose.
    References
    [3] R.M. Lanciano, M. Won, Coia Lr, et al., Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final re-port of the 1973 and 1978 patterns of care studies, Int. J. Radiat. Oncol. Biol. Phys. 20 (1991) 667–676. [4] Commission on Cancer's National Cancer Database. Cervix measure specifications (https://www.facs.org/~/media/files/quality%20programs/cancer/ncdb/measure% 20specs%20cervix.ashx). [5] Foundation for women's cancer quality indicators (https://www.sgo.org/quality-outcomes-and-research/quality-indicators/). [6] P.J. Eifel, A. Ho, N. Khalid, B. Erickson, J. Owen, Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study, Int. J. Radiat. Oncol. Biol. Phys. 89 (2014) 249–256.
    [7] Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 random-ized trials, J. Clin. Oncol. 26 (2008) 5802–5812.
    Contents lists available at ScienceDirect
    Journal of Magnetism and Magnetic Materials
    journal homepage: www.elsevier.com/locate/jmmm
    Research articles
    Cetuximab and Doxorubicin loaded dextran-coated Fe3O4 magnetic T
    nanoparticles as novel targeted nanocarriers for non-small cell lung cancer
    Qinlu Zhanga, Qian Liub, Menghan Dub, Alphons Vermorkenb, Yali Cuib, Lixia Zhangc, Lili Guob, Le Mab, , Mingwei Chena, a First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China
    b National Engineering Research Center for Miniaturized Detection Systems, Northwest University, Xi'an 710069, PR China
    c Department of 4μ8C Clinical Laboratory, Shaanxi Provincial People's Hospital, Xi'an 710069, PR China
    Keywords:
    Nanoparticles
    Drug targeting
    Non-small cell lung cancer
    Cetuximab
    Doxorubicin